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Abstract: The post-translational conversion of the ubiquitously expressed cellular form of 
the prion protein, PrPC, into its misfolded and pathogenic isoform, known as prion or PrPSc, 
plays a key role in prion diseases. These maladies are denoted transmissible spongiform 
encephalopathies (TSEs) and affect both humans and animals. A prerequisite for 
understanding TSEs is unraveling the molecular mechanism leading to the conversion 
process whereby most α-helical motifs are replaced by β-sheet secondary structures. 
Importantly, most point mutations linked to inherited prion diseases are clustered in the  
C-terminal domain region of PrPC and cause spontaneous conversion to PrPSc. Structural 
studies with PrP variants promise new clues regarding the proposed conversion mechanism 
and may help identify “hot spots” in PrPC involved in the pathogenic conversion. These 
investigations may also shed light on the early structural rearrangements occurring in some 
PrPC epitopes thought to be involved in modulating prion susceptibility. Here we present a 
detailed overview of our solution-state NMR studies on human prion protein carrying 
different pathological point mutations and the implications that such findings may have for 
the future of prion research. 
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1. Introduction 
The physiological cellular prion protein (PrP), PrPC, is a glycosylphosphatidylinositol  
(GPI)-anchored glycoprotein localized on the outer leaflet of the cellular membrane in mammalian 
cells. The mature human (Hu) PrPC (HuPrP) is composed of 209 residues including a largely 
unstructured N-terminal part and a globular α-helix rich C-terminal domain. Despite being highly 
conserved among mammals, its physiological function has not been established with certainty. 
Defining PrPC functions remains an absolute requirement for understanding transmissible spongiform 
encephalopathies (TSEs), or prion diseases, which are caused by the posttranslational conversion of 
PrPC into a misfolded and pathogenic isoform denoted prion or PrPSc. 
The term “prion” was coined by Stanley B. Prusiner in 1982, when he introduced the heretical 
notion of a small proteinaceous infectious particle as sole causal agent of TSEs in human and  
animals [1]. In humans, TSEs include a heterogeneous group of invariably fatal neurodegenerative 
diseases etiologically arising as sporadic, genetic or acquired. According to the recent classification, 
idiopathic forms include sporadic Creutzfeldt-Jakob disease (sCJD), sporadic fatal insomnia (sFI) and 
the variably protease sensitive prionopathies (VPSPr). Genetic forms comprise familial CJD (fCJD), 
Gerstmann-Sträussler-Scheinker disease (GSS), fatal familial insomnia (FFI) and prion protein 
cerebral amyloid angiopathy (PrP-CAA). The acquired forms are transmitted from human to human, as 
iatrogenic CJD (iCJD) or Kuru, from cattle to human, and human to human, as variant CJD (vCJD) [2]. 
In animals, relevant TSEs are scrapie in sheep and goats, bovine spongiform encephalopathy (BSE) in 
cattle, and chronic wasting disease (CWD) in deer, elk and moose [3]. 
From the epidemiological point of view, human TSEs are rare diseases evenly distributed 
worldwide. Sporadic CJD is the most frequent form and accounts for an incidence of about 0.6–1.2 per 
million per year [4]. Genetic forms account for 10%–15% of human prion diseases, whereas the 
acquired forms are negligible [5]. 
The main focus of research in prion biology is understanding the molecular mechanisms involved in 
the conformational conversion of PrPC to its pathological counterpart, PrPSc, and how prions trigger 
neurotoxic signals leading to TSEs. Genetic forms of human prion diseases are linked to specific 
mutations in the PrP gene (PRNP). Key evidence exists supporting the link between mutations and 
spontaneous conversion of PrPC to PrPSc in the brain. Over the past few years, biological studies on 
PrP pathological mutants have emerged as an invaluable tool for the comprehension of the molecular 
basis of TSEs. By means of different experimental approaches, several groups explored the use of the 
mutations in order to understand their effects on PrP structure and stability, elucidate the cellular 
events leading to PrP accumulation and misfolding, and explain the PrPC physiological roles and its 
neurotoxic potential [6–10]. 
In the next sections, we present an overview of our recent NMR structural studies on HuPrP 
pathological mutants. We solved and analyzed the structures corresponding to the globular domain  
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of different HuPrP constructs including the wild-type (WT), the V210I and Q212P mutants  
(linked to fCJD and GSS, respectively) and the E219K polymorphism. As a prelude, we first review 
what is currently known on PrPC structure and functions, PrPSc structural models, as well as genetic 
prion diseases. 
2. Structural Features of PrPC 
PRNP has been mapped in the short arm of chromosome 20 and the protein coding frame is present 
within a single exon [11]. PrPC is highly expressed within the central and peripheral nervous systems, 
although its content varies among distinct cell types, neurons and brain regions [12]. Expression of the 
protein is developmentally regulated in different mammalian species [13–17]. The immature form of 
PrPC is composed of 253 residues including an N-terminal endoplasmic reticulum (ER) signal peptide 
and a C-terminal GPI-anchoring signal peptide, which are cleaved during protein maturation and 
translocation to the extracellular side of the plasma membrane [18]. Similar to other GPI-anchored 
proteins, PrPC is found mainly attached to low density detergent insoluble membrane domains (DRMs) 
or lipid rafts [19]. 
Most structural information on PrPC came from bacterially expressed recombinant (rec) PrP. 
Despite the lack of Asn-linked glycosylation at residues 181 and 197, recPrP is structurally equivalent 
to brain-derived PrPC [20]. Atomic structures obtained by NMR techniques and X-ray crystallography 
revealed that recPrP shares a very similar fold across different mammalian species [7]. The full-length 
PrPC has a unique structure: while the N-terminal moiety is largely unfolded from residue 23 to 127, 
the C-terminus possesses a well-defined secondary and tertiary structure (residues 128–231, Figure 1b). 
The N-terminus features the octapeptide-repeat region (OR), an evolutionarily conserved motif 
whose repeated units can vary among species [21]. In HuPrP, the OR consists of one nonapeptide, 
PQGGGGWGQ (residues 51–59) and four repeats of sequence PHGGGWGQ (residues 60–92). 
Within the four repeats, histidines and tryptophan residues were found to be essential for the high 
affinity binding of copper ions and, to a lesser extent, of other divalent cations [22,23]. Additional 
histidines at position 96 and 111 are involved in high affinity copper binding and form the non-OR, or 
fifth, copper binding site [24,25] (Figure 1b). The positively charged segment, spanning residues 96–111, 
precedes a hydrophobic sequence (residues 112–127). These two biochemically distinct segments act 
in concert to control the co-translational translocation at the ER during PrPC biosynthesis [26,27]. 
The HuPrP C-terminal domain is composed of three α-helices (α1, α2 and α3) and two very short  
β-strands which form an antiparallel β-sheet (β1 and β2). Helices α2 and α3 form the bulk of the 
globular domain and are covalently bridged by a disulfide bond between Cys179 and Cys214. The  
C-terminus NMR structures of WT HuPrP obtained at different pH values (4.5, 5.5 and 7) show almost 
identical backbone tertiary structures with local differences in flexible regions [28–30].  
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Figure 1. (a) Secondary structure of the immature HuPrP with all the currently identified disease-associated mutations and polymorphisms 
(unclassified phenotype in gray; fCJD in black; GSS in red; PrP-CAA underlined; FFI in blue; and polymorphisms in green). The mature 
HuPrP consists of residues 23–231, while the N-terminal and C-terminal signal peptides are cleaved during protein maturation. In the lower 
panel, the frequency of the mutations and polymorphisms along the PRNP sequence is represented by colored rectangles. (b) Cartoon of the 
full-length HuPrP with the sequence-based representation of the disordered N-terminus and the structured C-terminal domain from PDB code 
2LSB [28]. Up to four Cu2+ ions are bound to the OR (residues 60–92) and one Cu2+ ions is bound to the non-OR (residues 93–111).  
(c) Schematic representation of the secondary elements in the C-terminal HuPrP structured domain. The stabilizing long-range interactions 
were inferred from structural analysis and published data [31–33]. Residues involved in disease-influential mutations or polymorphisms are labeled. 
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A detailed analysis reveals that HuPrP core structure is stabilized by extensive hydrophobic, 
aromatic and salt bridges networks between the β2-α2-α3 secondary elements and α3-α1 helices.  
These stabilizing interactions govern the proper folding of the C-terminal domain. Importantly,  
disease-related mutations are clustered almost in the folded part and may contribute to destabilize the 
native HuPrP conformation (Figure 1c) [31–34]. 
Among different species, local sequence and structural variations are prominently localized at the 
interface between the β2-α2 loop (residue 163–171) and the C-terminal part of α3-helix (residues 218–231), 
providing insights into a region of potential importance for pathogenicity and barriers to TSE 
transmission across species. Although this loop is highly flexible in most species, it shows a  
well-defined conformation in the recPrP of Syrian hamster [35], elk [36], bank vole [37], wallaby [38], 
rabbit [39] and horse [40]. In elk and bank vole recPrP, this rigidity was shown to be controlled by a 
single aminoacid substitution (S170N), whereas in wallaby, rabbit and horse recPrP it correlates with 
long-range interactions between residue 166 and 225. Importantly, no occurrence of TSE has been 
reported in rabbit, horse or any marsupial species, suggesting that prion resistance is enciphered by the 
amino acid composition of the β2-α2 loop and its stabilizing contacts with the C-terminal segment of 
α3-helix [41]. 
The PrPC N- and C-terminal domains are often considered structurally independent and  
non-interacting in prions. This view is supported by a body of evidence showing that the structured 
domain plays a crucial role during the pathological conversion to prions. In fact, limited protease  
K (PK) digestion of PrPSc often produces a smaller, protease-resistant segment of approximately  
142 amino acids spanning residue ~90 to 231 and referred to as PrP 27–30. This molecule is sufficient 
to generate infectious amyloid fibrils [42,43]. Additionally, in vitro generated amyloid fibrils 
composed only of C-terminal rec murine (Mo) PrP (residues 89–230) were pathogenic and infectious 
in transgenic (Tg) mice Tg9949 overexpressing MoPrP(89–230) [44]. Although the N-terminal region 
is not essential for prion conversion and infectivity, in the self-association of PrPC to PrPSc it may act 
as a modulator of both conversion and prion propagation [45]. 
Recent studies are attributing a significant role to the N-terminus in driving tertiary contacts with 
the C-terminus. By means of synchrotron-based X-ray absorption fine structure (XAFS) techniques, 
we showed that Q212P mutation, which is localized in α3-helix, alters the proper copper coordination 
in the non-OR copper binding site. These findings imply a structural effect of C-terminal mutations on 
the N-terminal part where functional domains are present [24]. Copper was shown to promote the 
association of the N-terminus to α1-helix [46]. Finally, zinc binding to the OR region induces novel 
electrostatic-driven contacts between this domain and the α2-α3 helices [47]. 
3. Defining PrPC Functions 
The physiological role of PrPC is usually disregarded at the expense of its role in TSEs. However its 
definition is essential to understand the molecular mechanisms leading to the disease. Common 
strategies often employed to identify PrPC functions include the development of different Tg mice lines 
which are knockout (KO) for PrP gene (Prnp). Despite the wide distribution of PrPC in the mammalian 
central nervous system (CNS), Prnp KO mice (Prnp0/0) surprisingly display no major anatomical 
developmental deficits [48]. Further evaluations revealed that Prnp0/0 mice show mild behavioral 
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phenotypes such as deficits in spatial learning and circadian rhythms [49], altered  
long-term potentiation [50,51] and increased excitability of hippocampal neurons [52–55]. These 
studies highlight the synaptic role of PrPC in the development of the hippocampus and are corroborated 
by immunohistochemical studies on PrPC expression and localization in the hippocampus during the 
development [13–17]. 
A neuroprotective PrPC function has been inferred from peculiar features of Prnp0/0 mice  
such as increased neuronal damage after ischemic stroke [56,57], increased mortality in excitotoxic  
conditions [58], enhanced susceptibility to kainate-induced seizure [59,60] and to glutamate treatment [61] 
and altered N-methyl-d-aspartate (NMDA) receptor currents with greater basal excitability, increased 
amplitude and slowed kinetics [62]. The observed neuroprotective roles of PrPC are consistent with the 
currently accepted idea that PrPC is a copper binding protein involved in copper homeostasis. A wealth 
of studies explored the functional aspects of this interaction indicating that the protein acts as a copper 
transporter, a sink of copper excess or a scavenger for copper-generated free radicals [63]. 
Insights into a possible PrPC involvement in cell proliferation and differentiation derive from results 
on embryonic hippocampal neuron cultures treated with recPrP showing an induced polarization in 
synapse development and neuritogenesis [64]. 
Finally, putative PrPC functions are based on its numerous interacting protein molecules [65,66]. 
Being a GPI-anchored protein present in the DRM, PrPC interacts both in cis or in trans with a variety 
of signaling molecules including, for instance, cavelolin-1, Fyn and Src tyrosines kinases [67], 
neuronal cell adhesion molecules (NCAMs) [68,69], stress-inducible protein 1 [70] and, recently, 
reelin [71], the NR2D subunit of the NMDA receptor [62] and the α2δ-1 subunit of the voltage gated 
calcium channel [72]. Taken together these studies reinforce the idea that PrPC is a pleiotropic protein 
with different functions, likely acting as a dynamic cell surface scaffolding protein for the assembly of 
signaling modules. 
4. Prion Conversion and PrPSc Molecular Models 
PrPC is the first biological system where a polypeptide exists in at least two distinct conformations 
associated with either physiological functions or disease. The central molecular event in the replication 
of mammalian prions is the self-propagating conformational conversion of PrPC to the misfolded PrPSc 
form. This postulate is known as the “protein-only” hypothesis [1]. 
Two different mechanisms of prion replication have been put forward. The “template assistance 
model” proposes that PrPSc exists as a monomer that is thermodynamically more stable than PrPC,  
but this favored conformer is kinetically inaccessible. In the rare event that a PrPSc is formed 
spontaneously (or provided exogenously) it can template the misfolding of PrPC by direct interaction. 
In this model, the critical step in the conversion is the formation of a dimer between PrPSc and PrPC,  
or a partially destabilized folding intermediate of PrPC denoted as PrP*. PrPSc acts as a template that 
catalyzes the refolding of PrPC to a thermodynamically more stable PrPSc conformation [73]. 
In the “nucleation-polymerization model” the conversion between PrPC and PrPSc is reversible,  
but the PrPSc monomer is much less stable than PrPC (i.e., the equilibrium is strongly toward PrPC). 
Stabilization of PrPSc occurs only upon formation of a stable oligomeric nucleus, which is 
thermodynamically not favorable. However, once the nucleus has formed, additional monomeric PrPC 
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is recruited and adopts the conformation of PrPSc. The rate-limiting step in this mechanism is not the 
conformational conversion itself but the nucleation step. This step, responsible for the lag phase in the 
spontaneous conversion, can be bypassed and accelerated by adding preformed PrPSc seeds [74]. 
One of the most important challenges in prion biology is determining the structural traits of 
infectious prions. Detailed information about PrPSc structure is crucial not only for understanding the 
molecular basis of conversion and transmission, but also for potential pharmacological intervention. 
Several spectroscopic studies revealed that the amyloid form of PrPSc is β-sheet enriched [75–80]. 
Numerous research groups investigated the molecular mechanism of the conversion by different 
methods (reviewed in [8]). However, all the structural studies on prions are limited by the disorder  
and insolubility of PrPSc and they still failed to identify its structure at the atomic level. Due to the lack 
of atomistic details for PrPSc, different prion models have been proposed based on low-resolution 
experimental approaches [81]. One such model is denoted as β-helical model. It is based on fiber  
X-ray diffraction and imaging simulation techniques on brain-extracted Syrian hamster fibrils. It 
proposes that the segment ~90–175 forms a four-stranded β-sheet core organized in a β-helical 
configuration, whereas α2 and α3 helices retain their native folding [82]. By contrast, hydrogen 
deuterium exchange experiments on brain-derived GPI-anchorless PrPSc showed that the region from 
residue ~90 to the entire C-terminus displays slow exchange rates which are typical for a structure 
consisting of a continuum of β-strands [83]. While recent X-ray diffraction data on different prion 
strains (Wille, H. University of Alberta, Edmonton, Alberta, Canada, unpublished data) seem to 
confirm the presence of cross-β structure consistent with the β-helical model, the latest work by 
Surewicz’s group [83] indicates that other structural PrPSc models cannot be ruled out. 
5. Genetic Human Prion Diseases: An Overview 
Genetic forms of HuTSEs are transmitted as autosomal dominant traits and co-segregate with 
missense or insertional/deletional mutations in PRNP. Over the last decades a number of CJD 
surveillance reports have identified up to 58 mutations linked to human prion diseases, associated with 
a heterogeneous spectrum of clinical and pathological phenotypes (Figure 1a). Missense mutations 
include 44 non-synonymous codon substitutions and five non-sense (or “stop”) mutations. Insertional 
or deletional mutations are exclusively localized in the OR, which normally contains one nonapeptide 
and four octapeptides. The insertions identified so far include one, two and four to nine extra 
octapeptides (OP), while only a deletion of two OP was reported [84]. Pathological point mutations 
have been found along the entire PRNP sequence but are mainly clustered in the C-terminal structured 
domain (residues 128 to 231) where about 39% of residues are implicated in disease-associated 
mutations. Interestingly, almost all the mutations that have been identified so far in the globular 
domain affect the hydrophobic and aromatic interactions and the salt bridges, which act in concert to 
stabilize the proper α-helical PrPC fold (Figure 1c). 
Pathological point mutations are classified into five clinical categories including fCJD, GSS, FFI, 
PrP-CAA and unclassified phenotype (Figure 1a). Although the mutations seem defined according to a 
rigid clinical classification, very often the syndromes overlap considerably. Only for a few mutations 
the prion transmissibility to model animals has been proved [2], therefore many genetic human prion 
diseases should be considered as proteinopathies. In general, these genetic forms show incomplete or 
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age-dependent penetrance, as frequently family members carrying a PRNP mutation do not develop 
prion diseases [85]. 
5.1. Clinico-Pathological Features of Genetic Human Prion Diseases 
The core features of fCJD include pathologically spongiform neurodegeneration, astrogliosis, 
neuronal loss and amyloid plaques, and clinically progressive dementia with visual, cerebellar  
and extrapyramidal signs and myoclonus [86]. Phenotypic diversity within sCJD and fCJD has been 
observed and most fCJD forms share features with specific subtypes of sCJD [87]. Several  
fCJD-associated mutations have been described. The most common fCJD-related mutations are 
E200K, V210I, E196K and +6OP insertion, which show distinct geographic clusters with high incidence 
of the disease [5,88]. Disease duration is highly variable—from weeks to less than two years [86]. 
FFI is caused by D178N mutation in combination with methionine at codon 129. It is characterized 
by insomnia, dysautonomia and motor signs associated mainly with thalamic astrogliosis, atrophy and 
spongiosis [89]. The established haplotypic relationships between D178N-M129 segregating with FFI 
and D178N-V129 segregating with fCJD [90] have been questioned by patients segregating with both 
FFI and fCJD phenotypes [91] or with different PRNP mutations showing a FFI-like syndrome [92]. 
Disease duration ranges from six to 42 months [86]. 
The histopathological presence of PrPSc plaque deposits, rather than the heterogeneous  
clinical features, defines GSS. Several point mutations are associated with this syndrome. The 
archetypal and most frequent GSS-related mutation is P102L. Other less frequently reported point 
mutations are P105L, A117V, H187R and F198S, while other mutations have been described in very 
few family cases [86,93]. 
All five non-sense mutations (Y145*, Q160*, Y163*, Y225* and Y226*) have attracted particular 
interest as they are associated with PrPSc amyloid deposition in the walls of arteries, arterioles, veins 
and capillaries of the CNS [93,94]. The vascular amyloid fibril deposits have been described in  
other neurodegenerative diseases, including Alzheimer’s disease, and are generally defined as cerebral 
amyloid angiopathy (CAA) or, in the case of PrP carrying premature stop codons, PrP-CAA [93]. 
Interestingly, a patient affected by Alzheimer’s disease with CAA showed PrPSc co-localization in the 
same amyloid deposits [95]. The reasons of PrPSc perivascular distribution are still unknown, although 
different Tg mice expressing anchorless PrP are now available [96–99]. The unique disease phenotype 
observed in PrP-CAA clearly indicates that the lack of GPI-moiety greatly contributes to the formation 
of PrPSc amyloid outside the cells and provides an intriguing link between prion diseases and other 
neurodegenerative diseases. 
For several other disease-associated mutations the clinico-pathological classification is still missing, 
because published data are insufficient and they are based only on genetic tests without detailed 
neuropathological and biochemical analyses. Often the new PRNP mutations have been reported in 
single patients without any family history for prion diseases, and are not associated with the presence 
of detectable PrPSc in the brain. Therefore the pathological role of such rare mutations remains to be 
assessed. Recently new unclassified mutations have been discovered including Q52P in the OP, 
D167N in the β2-α2 loop, N173K in α2-helix, V203G, V209M and Q212H in α3-helix [100,101]. Other 
confounding aspects are multiple mutations affecting the same codon and segregating with completely 
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different clinico-pathological features, for instance P105L (linked to GSS) and P105T/V (unclassified 
disease phenotype), D202N (GSS) and D202G (unclassified), E211Q (CJD) and E211N (GSS), Q212P 
(GSS) and Q212H (unclassified). 
5.2. Influential Polymorphisms in PRNP 
While point mutations are responsible for genetic prion diseases, some polymorphisms in PRNP 
influence the etiology and neuropathology of the disease. The polymorphic residue at codon 129 
(M129V) has been studied extensively. It has been shown that M129V may affect the susceptibility to 
prion diseases [102] and the incubation time of vCJD [103,104]. Methionine homozygosis at  
codon 129 is considered a risk factor for sCJD and iCJD [85,100,105]. 
Another naturally occurring HuPrP polymorphism, E219K, was found to protect against prion 
diseases. Heterozygosis at codon 219 was initially reported in the general Japanese population (allele 
frequency ~6%) [106,107] and was later found also in other Asiatic populations [108,109], but very 
rarely in Western Europeans [100,105]. The absence of confirmed cases of sCJD patients carrying the 
E219K polymorphism in Japan or Korea suggests that E219K heterozygosis acts as a protective  
factor to sCJD [110]. This polymorphism influences also the clinico-pathological features of both 
genetic [111–113] and acquired [114–117] prion diseases. Polymorphism at codon 127 (G127V) has 
been reported only among the natives of Papua New Guinea and is protective against Kuru [118]. 
Uncommon polymorphisms include the absence of 1OP [119], G54S, N171S [100] and G142S [108] 
which seem to have no susceptibility or unknown effects in HuTSEs. 
6. Structural Biology of HuPrP Pathological Mutants 
In the previous sections we overviewed the current knowledge on mutations and polymorphisms  
in PRNP and their clinico-pathological implications. Our understanding of the molecular mechanisms 
whereby mutations cause genetic TSEs still remains limited. It has been proposed that in vitro 
mutations may increase the likelihood of misfolding by thermodynamic destabilization of HuPrP. 
While this is true for few studied mutants [120–122], mutations may also alter the protein surface 
properties, triggering in turn abnormal interactions with other not yet identified cofactors [123,124]  
or causing aberrant cellular trafficking and accumulation inside the cells [125]. 
Structural studies on HuPrP carrying pathological mutations or polymorphisms may help to  
identify the regions involved in the misfolding to PrPSc. Recently, we attempted to determine the high 
resolution 3D NMR structure of the HuPrP carrying the Q212P and V210I mutations [126–128] linked 
to GSS and fCJD, respectively. Additionally, we solved the NMR structure of the CJD-protective 
polymorphism E219K and the WT HuPrP obtained under the same experimental conditions as the 
mutants [28]. Before our NMR structures, there was no clear evidence that a pathological point 
mutation may cause substantial structural difference in the HuPrP fold. Indeed, the fCJD-related 
E200K mutant (Figure 2c) exhibits minimal differences in the NMR structure [129] and dynamics to 
the WT protein [130]. The comparison of mutant structures with the WT HuPrP revealed that 
mutations introduce novel local structural differences, although the global tertiary fold remains very 
similar (Figure 2). 
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All the recHuPrP we analyzed were bacterially expressed in isotopic medium, purified from 
inclusion bodies and in vitro refolded [127,128]. Proteins always adopted a globular fold as indicated 
by the amide signal dispersion in the 1H-15N HSQC spectrum, providing a preliminary indication of 
sample suitability for NMR experiments. The backbone assignment was achieved with standard  
triple resonance experiments, including HNCA, HN(CO)CA, HNCACB and CBCA(CO)NH NMR 
experiments. 1H and 13C resonances of sidechains were assigned by analyses of 3D (H)CCH-TOCSY 
and 13C-edited NOESY-HSQC spectra. The large number of NOE restraints together with the 
completeness of resonance assignments (>95%) allowed us to determine the structure of all HuPrP 
mutants, the WT and E219K polymorphism with high resolution. 
Figure 2. Cartoon representations and backbone heavy atom overlays of the different WT 
and mutants HuPrP folded domains (residues 126–231): WT at pH 5.5 in red (a, PDB code 
2LSB), E219K in blue (b, PDB code 2LFT), E200K in light gray (c, PDB code 1FO7), 
Q212P in black (d, PDB code 2KUN), V210I at pH 5.5 in gray (e, PDB code 2LEJ) and  
(f) V210I at pH 7.2 in magenta (PDB code 2LV1) superimposed with the WT at pH 7 in 
green (PDB code 1HJN). The red frame on the WT (a) highlights the β2-α2 loop region. 
Black arrows point at the location of each mutation. 
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6.1. The Q212P Mutant NMR Structure 
The Q212P was the first mutation to attract our interest for structural investigations. Due to its 
unique sidechain features, proline is a well-known α-helix breaker. Pro212 interrupts the hydrogen 
(H)-bond with Arg208, increases the helix pitch and induces local rigidity in the α3-helix. Therefore 
we expected major structural rearrangements caused by this mutation, although it is associated with a 
very rare form of GSS characterized by mild amyloid PrPSc deposition and reduced penetrance [131,132]. 
Interestingly, the NMR structure of the Q212P mutant obtained at pH 5.5 revealed only minor changes 
at local level, between the segment from residue 205 to 220, but notable differences in distal regions. 
In particular, α3-helix showed a broken conformation at residue 221 and 222 which led to the 
formation of a novel highly flexible α-helix motif from residues 223 to 228 (Figure 2d). 
Upon P212 mutation, α3-helix exhibits small rotation along the helical axis with respect to the WT 
protein. A turn of α3-helix around Pro212 is altered to accommodate unfavorable steric interactions of 
proline with the preceding residue Glu211. The relative orientation of α3-helix with respect to the  
α2-helix changed from 51° in the WT to 33° in the Q212P mutant. As a result, several aromatic and 
hydrophobic interactions at the α2-α3 interface are lost. Major structural changes are observed in the  
β2-α2 loop region where the aromatic and hydrophobic clusters composed by Tyr163, Met166, Phe175, 
Tyr218 and Tyr225 are changed, showing increased exposure to the solvent and longer distance 
between the loop and the C-terminal part of α3-helix (Figure 3). 
6.2. NMR Structures of V210I at Two Physiological pH Values 
The V210I mutant is linked to fCJD, and it shows high incidence across European countries, e.g., in 
Italy where geographic clusters carrying this mutation have been identified [133]. Val210 is located in 
the middle of the α3-helix and it is part of tightly packed hydrophobic and aromatic residues present  
at the interfaces between the α2 and α3 helices and β2 strand (Figure 1c). Therefore we expected this 
mutation to promote misfolding by altering these stabilizing interactions. 
We investigated the effect of V210I on HuPrP structure at two different physiological pH values. 
Acidic pH conditions are characteristic of the intracellular endosomial compartments [134] where  
PrPC is sequestered during its internalization. Reports using cell culture models proposed that  
PrPC misfolding and accumulation may occur during endocytosis in both late and recycling  
endosomes [135–137]. 
At pH 5.5 the Ile210 causes steric crowding in the inter-helical interface. V210I mutation induces 
reorientations of several residues involved in α2–α3 hydrophobic interactions. In order to accommodate 
unfavorable steric interactions with Ile210, the sidechain of Val180 changed its conformation along  
Cα-Cβ bond by 180°. In addition, the mutation significantly altered the orientation of sidechains of 
Val176 and Ile184, thus influencing their hydrophobic contacts with other residues. Interestingly,  
as a consequence of these rearrangements the α2-helix is distorted (Figure 2e). Also in this case the  
inter-helical angle changes from 51° in the WT to 23° in V210I. Another region within the globular 
domain of V210I mutant that displays interesting structural features is the interface of α1 and α3 
helices. Helix α1 in the mutant exhibits a reduced propensity to form tertiary hydrophobic  
interactions with the protein core. The β2–α2 loop region in V210I is poorly defined, shows an altered 
Molecules 2013, 18 9462 
 
 
conformation and an increased distance from the α3-helix as observed also in the Q212P  
mutant (Figure 3). 
Figure 3. (a) Distances in Å between residues Met166 and Tyr218 within the β2-α2 loop 
and of α3-helix in different WT and mutant HuPrP structures. Distances were calculated 
using VMD software [138]. (b) Cartoon representations and backbone heavy atoms 
overlays of WT at pH 5.5, E219K and V210I at pH 7.2. This peculiar view highlights the 
different spacing observed among the HuPrP structures between the β2-α2 loop and those of 
α3-helix. (c) Average values of solvent accessibility (%) for selected residues in different 
WT and mutant HuPrP structures calculated using GETAREA software [139]. (d) Cartoon 
representations and backbone heavy atom overlays of WT and Q212P structures. Selected 
hydrophobic and aromatic residues are highlighted. 
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Comparison with V210I obtained at pH 7.2 showed that changing pH from 5.5 to neutral condition 
barely affects the global architecture of the protein (Figure 2f). However, a careful inspection revealed 
local structural differences between the two V210I structures. The most prominent pH-related changes 
involve alterations in interactions within the hydrophobic core. At pH 5.5, several hydrophobic 
contacts between residues at the α2–α3 interface are lost. Moreover, at neutral pH the V210I mutant 
exhibits a more compact packing of hydrophobic residues at the interface of the β1–α1 loop and α1 and 
α3 helices. Additional stabilizing interactions at these interfaces are provided through hydrophobic 
contacts between Phe141 and Tyr145, Tyr145 and Tyr149, Tyr145 and Met209, and Met154 and 
Val209, which are not present at acidic condition. In addition to electrostatic interactions that stabilize 
the highly hydrophilic part of α1-helix (Asp147−Arg151 and Glu146-Lys204 salt bridges), 
hydrophobic interactions are important for maintaining the stability of α1-helix and for its interactions 
with other parts of the globular domain of HuPrP (Figure 1c). Taken together, the resulting 
comparisons of NMR structures of V210I obtained at two pH values indicate that the separation of  
the β1−α1 loop, α1-helix, and the α1−β2 loop from the α2−α3 region is a hot “spot” during the transition 
from neutral to acidic pH, and it is required during the early stages of the conversion process. In 
support of this view, molecular dynamics (MD) experiments highlighted the role of α1-helix in the 
early steps of PrPC misfolding induced by a decrease in pH [140–142]. According to these MD studies, 
lowering the pH induces a loss of contacts between α1-helix and other secondary structure elements in 
the globular domain of HuPrP, as we observed in our V210I mutant structures. 
6.3. NMR Structures of WT HuPrP and of HuPrP Containing E219K Protective Polymorphism 
The naturally occurring HuPrP polymorphism, E219K, attracted interest because it was found to 
protect against prion diseases. Heterozygosis at codon 219 was initially reported in the Japanese 
population [107]. The lack of confirmed cases of sCJD patients carrying the E219K polymorphism  
led to the conclusion that E219K heterozygosis acts as a protective factor against sCJD. This 
characteristic, also denoted as “dominant-negative effect”, has been reported in several experimental 
studies both in vivo and in vitro [123,143–147]. The structural basis responsible for the protective 
effect of the E219K polymorphism has so far remained elusive. To gain insight into the structural 
determinants underlying the protective influence of this naturally occurring polymorphism, we 
determined its high-resolution 3D structure based on NMR datasets. Because we expected minor local 
structural changes, we solved also the WT HuPrP obtained under exactly the same experimental 
conditions used for mutants and E219K polymorphism (Figure 2a). 
The 3D structure of WT HuPrP at pH 5.5 is very similar to the previously reported structure of  
the WT protein resolved at pH 4.5 [30]. The two structures are superimposable on the backbone atoms 
with an r.m.s.d. value of 1.1 Å. The most apparent differences occur within the β2-α2 loop  
region referring to a different orientation of the Tyr169. At pH 4.5 this residue points toward the 
interior of the protein, whereas at pH 5.5 it is exposed to solvent, thus loosing contacts with nearby 
aromatic residues. 
The folded domains of E219K and WT revealed that they are very similar, with backbone r.m.s.d. 
of only 1.33 Å. Substitution of Glu by Lys at position 219 apparently does not induce substantial local 
structural changes (Figure 2b). Nevertheless, the 3D structure of E219K pointed to rearrangements of 
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some residues in the β1-α1 loop (Phe141), α1-helix (Tyr145 and Tyr149) and α1-β2 loop (Tyr157) that 
affected their mutual hydrophobic interactions with residues in α3-helix. NOE data revealed close 
packing between the sidechains of several residues situated at the interface of β1-α1 loop, α1-helix,  
α1-β2 loop and α3-helix. The sidechain of Phe141 is directed towards the α1-α3 inter-helical interface 
engaged in π-π interactions with Tyr149 and Tyr150. These three aromatic residues form a 
hydrophobic cluster. Tertiary contacts are also manifested through pronounced hydrophobic 
interactions of Phe141, Tyr149 and Tyr150 with Met205, and Phe141 and Tyr150 with Val209. 
Moreover, the interface of β1-α1 loop, α1-helix, α1-β2 loop and α3-helix is further stabilized through 
hydrophobic interactions of Tyr157 with Met206 and Val209. The structurally poorly defined β2-α2 
loop region also exhibited rearrangements involving both hydrophobic and electrostatic interactions. 
Especially pronounced contacts involve Met166 and Phe175 located in the loop region and Tyr218  
and Tyr225 in the α3-helix (Figure 3). Although the E219K did not induce significant local structural 
changes, this polymorphism has a marked effect on the distribution of electrostatic surface potential. 
Unlike the WT, large areas of positive charge are observed on the surface of the E219K. These 
variations of surface electrostatic potential between the two proteins are mostly clustered around the 
site of substitution, at the interface of β2-α2 loop and the C-terminal end of α3-helix, and at the  
N-terminal part of α3-helix. In the WT the area around the residue at position 219 is negatively charged 
or neutral, whereas in E219K the corresponding region is mostly positively charged. 
In conclusion, the NMR structure of the E219K polymorphism suggests that the structural 
determinants for its dominant-negative effect are enciphered by the perturbation of the surface charge, 
and by subtle structural rearrangements most prominently localized in the β2-α2 loop region and at the 
interface of β1-α1 loop, α1-helix, α1-β2 loop and α3-helix. Variations in the distribution of electrostatic 
potential on the surface of E219K with respect to the WT are remarkable, considering that only 
individuals heterozygous at codon 219 seem resistant to sCJD. Our findings suggest that different 
distribution of charges in the WT and E219K may facilitate intermolecular interactions between  
the two allelic variants, thus sequestering them from the early stages of the fibrillization process or 
inhibiting interactions with yet unknown facilitators of prion conversion. 
6.4. Common Structural Traits in HuPrP Pathological Mutants 
The structural comparison of the mutants with the WT HuPrP structures allowed us to draw some 
preliminary conclusions towards the identification of common regions involved in the early stage of 
the conversion process to PrPSc. The observed variations are mostly clustered at the interface between 
the β2-α2 loop and α3-helix. In particular, mutations alter the stabilizing interactions occurring in this 
region by promoting the progressive separation of the loop from the C-terminal part of α3-helix to the 
solvent. This increased distance upon mutation is clearly illustrated in Figure 3a,b. While in WT 
HuPrP solved at pH 5.5 the distance between Met166 and Tyr218 is 6.4 ± 0.1 Å, in Q212P and V210I 
it greatly increases up to 14.7 ± 0.4 Å. It is noteworthy that in E219K the same residues are much more 
closed, thus indicating that the protective polymorphism exhibits a more compact packing at the  
β2-α2 loop interface. Interestingly, the β2–α2 loop in E219K displays a tendency toward 310-helical 
conformation, thus being somewhat better defined with respect to the same region in the WT and other 
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disease-related mutants. These local structural features of the polymorphism may further account for 
its protective influence against sCJD. 
Additionally, unlike the WT and E219K, the pathological mutants are characterized by exposure of 
hydrophobic and aromatic residues to the solvent in different structural regions. At acidic pH, in  
V210I the hydrophobic residues (Ile139, Met154 and Pro158) are much more solvent exposed at the 
α1-α3 interface rather than the same mutant structure at pH 7.2 (Figure 3c,d). Conversely, the  
Q212P showed increased exposition of the hydrophobic core in the β2-α2 loop and C-terminal part of  
α3-helix (Figure 3c,d). 
Several groups investigated by molecular dynamics the structural effect of different HuPrP 
pathological mutants, including also V210I, E200K, Q212P and E219K [32,33,148–150]. These 
studies highlight the possible role of mutations on the flexibility of the β2–α2 loop and on the 
hydrophobic core organization, corroborating the NMR results. 
7. Conclusions 
Experimental evidence supports the hypothesis that the increased hydrophobicity of PrPC is  
one of the main determinants of toxicity. Earlier studies proposed a mechanism of neurotoxicity  
through a direct interaction of PrPSc, or partially unfolded intermediate states, with neuronal  
membranes [151,152], supporting the hypothesis that altered membrane association of PrPC may be an 
important factor during the conversion to prion [153,154]. By means of spectroscopic and cellular 
techniques, several authors have shown that mild denaturation of recHuPrP leads to an increased 
exposure of the hydrophobic region that facilitates internalization and neurotoxic intracellular 
accumulation [155,156]. Cell treatment with recombinant HuPrP carrying disease-related mutations 
induces higher intracellular retention and neurotoxicity of both native and partially denaturated 
conformations [157]. Protein folding metastable intermediates are usually characterized by a 
significant exposure of hydrophobic residues which facilitates intermolecular interactions [158–160].  
It has been proposed that the membrane environments may alter the PrPC conformational structure. 
Spectroscopic studies performed on α-helix folded full-length recHuPrP showed a direct interaction of 
the protein with acidic vesicles containing acidic phosphatidylserine (POPS). The binding to POPS 
seems to occur at mildly acidic pH values and it involves only the N-terminal segment, while the 
globular domain retains its native conformation [161]. In further studies, the effect of different types of 
lipid membranes on recPrP structure was investigated by circular dichroism and Fourier transform 
infra red spectroscopy experiments [162,163]. These data showed that recPrP maintains its α-helix 
conformation when interacting with lipid raft-like membranes rich in cholesterol and sphingomyelin at 
pH 7. However, the binding of the protein to negatively charged lipid vesicles, such as the POPG 
membranes, promotes structural changes in β-sheet enriched structures at pH 5 and, to a lesser extent, 
at pH 7. Thus, the presented results clearly indicate that the preferred PrPC localization in the lipid raft 
domains contributes to its stabilization in the α-helix structure. Altered PrP association with different 
lipid membranes, such as those in the endocytic compartments, may contribute to destabilize the native 
PrPC fold. 
In conclusion, our findings on disease-associated mutants and the E219K polymorphism provide 
new clues on the possible early events of HuPrP misfolding. The structural disorder of the β2–α2 loop, 
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together with the increased distance between this loop and α3-helix observed in different mutants, lead 
to exposure of hydrophobic residues to solvent, thus facilitating intermolecular interactions with other 
PrP or with yet unknown cellular factors and abnormal accumulation inside the cells. 
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